An NDA must include data from studies conducted outside the United States.

An NDA must include data from studies conducted outside the United States.

• A. Data from studies conducted outside the U.S.
• B. Manufacturing plant lease
• C. Market share forecasts
• D. Company annual report

Answer: (A)

When preparing a New Drug Application, regulators expect data from studies conducted outside the United States. Including international study data helps demonstrate that the drug’s safety and efficacy are consistent across different populations and settings, which supports global labeling and approval decisions. Differences in genetics, environment, or concomitant medications can influence outcomes, so international data contributes to a more complete risk-benefit assessment. The other items—such as a facility lease, marketing forecasts, or a company annual report—do not provide the clinical evidence needed for regulatory review, so they aren’t required parts of the NDA submission.

When preparing a New Drug Application, regulators expect data from studies conducted outside the United States. Including international study data helps demonstrate that the drug’s safety and efficacy are consistent across different populations and settings, which supports global labeling and approval decisions. Differences in genetics, environment, or concomitant medications can influence outcomes, so international data contributes to a more complete risk-benefit assessment. The other items—such as a facility lease, marketing forecasts, or a company annual report—do not provide the clinical evidence needed for regulatory review, so they aren’t required parts of the NDA submission.